Treatment changes or delays stemming from cancer drug shortages lead to worse outcomes and higher costs, according to a national  survey  to be published in the April 1 issue of the  American Journal of Health-System Pharmacy.

Researchers analyzed responses from 243 oncology pharmacists and other health professionals involved in managing cancer drug shortages for academic medical centers, community hospitals and other cancer treatment facilities.

Thanks to drug shortages, 93 percent reported delays in chemotherapy administration or changes in treatment regimens, 85 percent saw higher costs and 10 percent experienced reimbursement challenges.

Read Article:  FIERCEHEALTHCARE

Contact: MKK – Attorneys at Law:       1-877-NJLAW4U